Two new targeted treatments
are now approved by the
Therapeutic Goods Administration
(TGA) for patients with HER2-
positive breast cancer and
headline the start of Breast Cancer
Awareness Month.
Sydney oncologist Professor Fran
Boyle has welcomed the approval
of the new therapies.
“The approval of pertuzumab
and trastuzumab emtansine is the
result of years of research into the
HER2 pathway and is an advance
for treatment of this faster growing
form of breast cancer, which has in
the past been associated with poor
prognosis,” she said.The above article was sent to subscribers in Pharmacy Daily's issue from 16 Oct 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 16 Oct 13
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.